CGNT Cognyte Software Ltd.

Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.

$24.76  -0.07 (-0.28%)
As of 07/23/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Information Technology
Industry:  Software—Infrastructure
Index country:  Israel
Country of incorporation:  Israel
IPO date:  01/28/2021
Outstanding shares:  65,773,335
Average volume:  367,045
Market cap:   $1,633,151,908
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    M25133105
ISIN:        IL0011691438
Sedol:      BMYDNT8
Valuation   (See tab for details)
PE ratio:   6,451.28
PB ratio:   6.02
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy